REGISTERED PLAN PRIVATE INVESTMENTS INC.

Registered Plan Private Investments Inc.

Equities

LXGTF

CA5290204067

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 12:38:47 2024-05-17 EDT			5-day change	1st Jan Change
0.000001 ^USD	-90.00%		-.--%	-.--%

05-24	Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-01	Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Lexington Biosciences, Inc. Announces Board Appointments

July 06, 2017 at 12:31 pm

Lexington Biosciences, Inc. announced to introduce Rocco Rossi and Bryan Disher to its Board. Rossi currently serves as President and CEO of Prostate Cancer Canada. Disher spent 38 years with PricewaterhouseCoopers (PwC) in Canada, Australia and Ukraine.

Latest news about Registered Plan Private Investments Inc.

Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-24	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-04	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt	23-05-01	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-29	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-02	CI
Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt	22-05-01	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-28	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-31	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-29	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-31	CI
Lexington Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-01	CI
Lexington Biosciences, Inc. Approves the Election of Tamara Manuel as Director	20-04-27	CI
Lexington Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-21	CI
Lexington Biosciences, Inc. Announces Executive Changes	20-04-16	CI
Lexington Biosciences, Inc. announced that it expects to receive CAD 0.5 million in funding	20-02-19	CI
Lexington Biosciences Updates on License Termination	20-02-12	CI
Lexington Biosciences, Inc. Announces the Resignation of Eric Willis as its CEO & Director	20-02-12	CI

Chart Registered Plan Private Investments Inc.

Duration

Period

Chart Registered Plan Private Investments Inc.

More charts

Company Profile

Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a personâs vascular endothelium - the vital innermost lining of a personâs cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a personâs cardiovascular health.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
REGISTERED PLAN PRIVATE INVESTMENTS INC.	-.--%	27
ABBOTT LABORATORIES	-7.03%	178B
MEDTRONIC PLC	-6.32%	98.95B
BECTON, DICKINSON AND COMPANY	-6.15%	66.14B
DEXCOM, INC.	-10.62%	44.11B
CENCORA, INC.	+8.34%	43.82B
HOYA CORPORATION	+11.91%	42.07B
METTLER-TOLEDO INTERNATIONAL, INC.	+11.64%	28.92B
TERUMO CORPORATION	+17.68%	24.69B
WEST PHARMACEUTICAL SERVICES, INC.	-8.87%	23.38B

Other Medical Equipment, Supplies & Distribution